Literature DB >> 23053176

Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis.

Burçin Tezcanlı Kaymaz1, Nur Selvi, Cumhur Gündüz, Cağdaş Aktan, Ayşegül Dalmızrak, Güray Saydam, Buket Kosova.   

Abstract

Signal transducers and activators of transcription (STAT) proteins are latent cytoplasmic transcription factors that affect several cellular processes including cell growth, proliferation, differentiation, and survival. Following phosphorylation, STATs are activated, and their upregulated expressions increase in malignancies with playing a role in the development of leukemia. In this study, transfection of K-562 cells with either unmodified or chemically modified anti-STAT3, -STAT5A, -STAT5B siRNAs for duration of 12 days, determining gene silencing at mRNA and protein levels, evaluating apoptosis rate, and detecting JAK/STAT pathway members' gene expression profiles via array method were aimed. Quantitative RT-PCR and Western blot assays indicated that STAT expressions were downregulated both at mRNA and protein levels, and TUNEL assay showed that leukemic cell apoptosis was induced due to inhibition of STATs. Array analysis resulted with decreases in signal transducer, phosphorylation inducer, and oncogene expressions, whereas increased expressions in STAT inhibitor and apoptosis inducer genes were observed. These results point out that siRNA application could constitute a new and alternative curative method for supporting therapy of CML-diagnosed patients in the future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053176     DOI: 10.1007/s00277-012-1575-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  6 in total

1.  Investigating the potential therapeutic role of targeting STAT3 for overcoming drug resistance by regulating energy metabolism in chronic myeloid leukemia cells.

Authors:  Burcin Tezcanli Kaymaz; Nur Selvi Gunel; Fatma Sogutlu; Neslihan Pinar Ozates Ay; Yusuf Baran; Cumhur Gunduz; Cigir Biray Avci
Journal:  Iran J Basic Med Sci       Date:  2022-07       Impact factor: 2.532

2.  Suppression of STAT5A and STAT5B chronic myeloid leukemia cells via siRNA and antisense-oligonucleotide applications with the induction of apoptosis.

Authors:  Burçin Tezcanlı Kaymaz; Nur Selvi; Aysun Adan Gokbulut; Cağdaş Aktan; Cumhur Gündüz; Güray Saydam; Fahri Sahin; Vildan Bozok Cetintaş; Yusuf Baran; Buket Kosova
Journal:  Am J Blood Res       Date:  2013-01-17

3.  MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin.

Authors:  Burçin Tezcanlı Kaymaz; Vildan Bozok Cetintaş; Cağdaş Aktan; Buket Kosova
Journal:  Tumour Biol       Date:  2014-05-30

4.  Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.

Authors:  Burçin Tezcanlı Kaymaz; Nur Selvi Günel; Metin Ceyhan; Vildan Bozok Çetintaş; Buket Özel; Melis Kartal Yandım; Sezgi Kıpçak; Çağdaş Aktan; Aysun Adan Gökbulut; Yusuf Baran; Buket Kosova Can
Journal:  Tumour Biol       Date:  2015-05-08

Review 5.  Nanoparticles Targeting STATs in Cancer Therapy.

Authors:  Milad Ashrafizadeh; Zahra Ahmadi; Niranjan G Kotla; Elham Ghasemipour Afshar; Saeed Samarghandian; Ali Mandegary; Abbas Pardakhty; Reza Mohammadinejad; Gautam Sethi
Journal:  Cells       Date:  2019-09-27       Impact factor: 6.600

Review 6.  STAT inhibitors for cancer therapy.

Authors:  Muhammad Furqan; Akintunde Akinleye; Nikhil Mukhi; Varun Mittal; Yamei Chen; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-12-05       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.